Plain-English translation of NCT05511623 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether adding —a medication that helps your immune system fight cancer—to standard cervical cancer treatment works better than the standard treatment alone. All participants receive radiation therapy combined with chemotherapy (cisplatin). Half also receive the new medication every three weeks for up to one year. Researchers want to see if this combination helps more patients and is safe to use.
Cervical cancer at stage IIIC2 is advanced, and while radiation plus chemotherapy is the standard treatment, doctors are looking for ways to improve survival rates and help patients live longer. This medication works by 'waking up' the immune system to recognize and attack cancer cells more effectively.
You likely qualify if…
You likely don't qualify if…
You will receive five weeks of radiation therapy to the pelvis combined with weekly chemotherapy infusions. If you are randomly assigned to the experimental group, you will also receive intravenous infusions of the new medication every three weeks, continuing for up to one year unless your cancer worsens or side effects become too severe. You will have regular blood tests and imaging scans to monitor how well the treatment is working and to check for side effects.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
First Affiliated Hospital of Guangxi Medical University
Enrollment target
~112 participants
Started
September 2022
Primary completion
December 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 70 Years
Sex
Female only
Last updated on clinicaltrials.gov in September 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
shanshan ma, M.D.
First Affiliated Hospital of Guangxi Medical University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.